期刊
KOREAN CIRCULATION JOURNAL
卷 47, 期 5, 页码 663-669出版社
KOREAN SOC CARDIOLOGY
DOI: 10.4070/kcj.2017.0028
关键词
Gut epithelial barrier; Gastrointestinal microbiome; Dysbiosis; Microbe-derived metabolites
资金
- Japan Society for the Promotion of Science [KAKENHI 26670395]
- Takeda Pharmaceutical Co., Ltd.
- Daiichi Sankyo Co., Ltd.
- Shionogi Co., Ltd.
- Nippon Boehringer Ingelheim Co., Ltd.
- Bristol-Myers Squibb K.K.
- MSD K.K.
- Sanofi K.K.
- Mitsubishi Tanabe Pharma Corporation
- Sumitomo Dainippon Pharma Co., Ltd.
Patients with heart failure (HF) have structural and functional changes of the gut as a result of microcirculatory disturbances. A disrupted gut epithelial barrier may lead to translocation of microbial products into systemic circulation, possibly aggravating HF by inducing inflammatory responses. Gut microbiota play an essential role in the maintenance of host homeostasis because large quantities of their gene products complement host physiological processes. Emerging evidence has suggested the potential clinical significance of gut microbiota in the pathophysiology of HF. Imbalances of gut microbe-derived metabolites can contribute to cardiac dysfunction and other morbidities in patients with HF. Therapeutic research for HF through targeting microbiota is under way. Thus, the novel concept of a heart-gut axis may lead to breakthroughs in the development of innovative diagnostics and therapeutic approaches for HF.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据